Market Size of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma in the 6MM is anticipated to be USD 2796.2 Million in 2030. Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the United States. Advancements in technology, Increased collaborations & acquisitions and Competition among biotech and pharma giants are some of the factors expected to drive the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market in the coming years. The key players in the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market include Novartis, Kite Pharma, Gilead Sciences, Celgene Corporation and others.